Can Lab-Grown tumors stop breast cancer from coming back?
NCT ID NCT05464082
First seen Feb 24, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study is testing a new approach called Functional Precision Oncology for people with triple-negative or HR-low/HER2- breast cancer at high risk of early recurrence. Researchers will create personalized tumor models (in mice and lab dishes) from each patient's cancer to find the most effective treatments. The goal is to see if this method can predict and prevent the cancer from returning early. The study involves 80 participants and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Functional Precision Oncology (tumor models including patient-derived xenografts and organoids)
What this could lead to
If successful, this approach could help doctors identify the most effective treatments for each patient's unique tumor, potentially reducing the risk of early cancer return.
What could go wrong
This is a small, early-phase study (80 participants) focused on feasibility, not a proven treatment. The tumor models may not always predict real patient responses, and the approach may not improve outcomes for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.